论文部分内容阅读
目的探讨单唾液酸四已糖神经节苷脂(GM1)对手足口病合并病毒性脑炎的治疗作用。方法选择手足口病合并病毒性脑炎患者60例,随机分为治疗组30例、对照组30例。两组均给予丙种球蛋白、甲基泼尼松龙冲击及脱水、抗病毒等治疗。治疗组加用GM1每天20mg,加入5%GS50ml静脉滴注,14d为一疗程;对照组加用胞二磷胆碱每天0.25,加入5%GS50ml静脉滴注,14d为一疗程,观察比较两组的治疗效果。结果治疗组疗效优于对照组(P<0.05)。结论 GM1治疗手足口病合并病毒性脑炎安全有效,可以在临床推广使用。
Objective To investigate the therapeutic effect of monosialotetraosyl ganglioside (GM1) on hand-foot-mouth disease with viral encephalitis. Methods Sixty patients with HFMD complicated with viral encephalitis were randomly divided into treatment group (30 cases) and control group (30 cases). Both groups were given gamma globulin, methylprednisolone impact and dehydration, antiviral therapy. The treatment group plus GM1 daily 20mg, adding 5% GS50ml intravenous drip, 14d for a course of treatment; control group plus citicoline daily 0.25, adding 5% GS50ml intravenous drip, 14d for a course of treatment were observed and compared two groups Therapeutic effect. Results The treatment group was better than the control group (P <0.05). Conclusion GM1 is safe and effective in the treatment of hand, foot and mouth disease with viral encephalitis, and can be used clinically.